Home > Boards > US OTC > Medical - Equipment >

Solos Endoscopy, Inc. (SNDY)

SNDY RSS Feed
Add SNDY Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator Marilynt, Bopper155, slazenger7, cubs, Aqua, blueskies
Search This Board:
Last Post: 7/22/2014 1:18:05 PM - Followers: 615 - Board type: Free - Posts Today: 1


 
= Share Structure - Updated 10/21/2013=
 
Market Value $2,813,198 Updated 01/28/2014
Shares Outstanding
1,518,654,723 
Updated 7/14/2014
Float 1,503,191,864 Updated 7/14/2014
Authorized Shares 2,900,000,000 Updated 7/14/2014
Restricted Shares 15,462,859 Updated 7/14/2014












 
= Officers/Directors =


Robert Segersten_CEO_President_Treasurer_Director
Amanda Segersten_Secretary_Vice President
Fred Schiemann_CFO_Director

Nevada SOS

Robert Segersten_President of Solos Endoscopy
Robert Segersten, President Treasurer and Director: Mr. Segersten founded Woodbine Optical Corporation in 1991 in order to produce OEM video cameras for the medical marketplace. The company quickly added light sources, video couplers and relay lens to its product offering. Woodbine procured large OEM contracts from companies like Bircher Medical, Olympus, and ConMed. His relationship with Bircher Medical allowed Woodbine the opportunity to acquire the Solos Endoscopy Video division of Bircher. He successfully merged Solos into Woodbine and renamed the company - Solos Endoscopy capitalizing on the strong brand recognition of Solos. He grew the company to approximately $3 million in sales, at which time he was approached by EndoImage and sold Solos in 1994. He stayed on as President until 1996. He remained an advisor to the company until he reacquired ownership in 2000. He is a graduate of Bates College and received his law degree from Boston University.

Amanda Segersten_Vice President of Solos Endoscopy
Amanda Segersten attended Johnson and Wales University and has been employed by Solos Endoscopy since 2000.

Fred Schiemann_CFO of Solos Endoscopy
Fred Schiemann previously served as the Chief Financial Officer of Xtreme Oil & Gas, Inc. Prior to that, he has held CFO positions in several corporations and currently serves as Treasurer of Biz2Biz.com. His educational background includes an undergraduate degree from the University of Illinois, Chicago Circle Campus as well as an MBA in taxation from Golden Gate University, Sacramento campus. During his years of practice, he has been involved with many public registrations and structuring of mergers and acquisitions. His current practice includes an emphasis on administration and consulting to small and micro-cap public companies.


= Business Summary =

Solos Endoscopy, Inc. develops and markets technology, applications, medical devices, and procedural techniques for the screening, diagnosis, treatment, and management of medical conditions. It primarily offers rigid endoscopes, hand held surgical instruments, and video equipment for the minimally invasive surgery market. The company's products include digital imaging systems; three-chip and one-chip camera systems, and three-chip cameras; cameras and accessories; rigid scopes comprising laparoscopes, operative scopes, cystoscopes, and scope trays; and endoscopic instruments, such as dissectors, graspers, scissors, needle holders, fan retractors, cautery instruments, insufflation needles, and clip applying forceps. Its products also comprise laparoscopic instruments, including general surgery, lymphadenectomy, gynecology, and thorascopy instruments; trocar and cannula sets, cannulas, trocars, reducer sleeves, and seals; monitors and video carts; video equipment and accessories; illumination instruments, such as fiber optic cables, light port adapters, light sources, and replacement lamps; and insufflators. In addition, Solos offers ENT products for tymplanoplasty, endoscopic sinus surgery, and septorhinoplasty; bariatric instruments; and insulated and non-insulated handles. It markets its products to hospitals, surgery centers, and physician offices through direct sales and it's Web site. The company was formerly known as ViaDux Health, Inc. and changed its name to Solos Endoscopy, Inc. in March 2006. Solos Endoscopy was founded in 1986 and is based in Boston, Massachusetts.



= Company =

About Solos Endoscopy, Inc.:

Solos Endoscopy, Inc. is a healthcare technology company that develops and markets technology,  applications, medical devices and procedural techniques for the screening, diagnosis, treatment and   management of medical conditions. The Company has several dozen products, mainly rigid endoscopes,  hand held surgical instruments and video equipment for the minimally invasive surgery market, all of  which can be found on its website at: www.solosendoscopy.com. The Company markets its products to  hospitals, surgery centers and physician offices.



Additional information on its  FDA approved products is available on the Company's website at:  www.solosendoscopy.com.



65 Sprague Street
West B

Boston, MA 02136


The office is approximately 6,000 square feet.

Phone: 617-360-9700
E-mail: info@solosendoscopy.com 

Investor Relations Phone: 1-617-360-9719
Transfer Agent:
Pacific Stock Transfer
4045 South Spencer Street, Ste. 403
Las Vegas, NV 89119
702-361-3033
Registered Under Exchange Act: Yes
Regulatory Authority: Security Exchange Commission (SEC)


= Press Releases = 
Solos Endoscopy Receives ISO 13485:2003 Certification From TUV SUD America
http://www.otcmarkets.com/stock/SNDY/news/Solos-Endoscopy-and-TUV-SUD-America-Schedule-Stage-1-ISO-13485-Audit-for-February-26--2013?id=57836&b=y

Solos Endoscopy and TUV SUD America Schedule Stage 2 ISO 13485 Audit for August 16, 2013
http://www.otcmarkets.com/stock/SNDY/news/Solos-Endoscopy-and-TUV-SUD-America-Schedule-Stage-1-ISO-13485-Audit-for-February-26--2013?id=57836&b=y

Solos Endoscopy and TUV SUD America Schedule Stage 1 ISO 13485 Audit for February 26, 2013
http://www.otcmarkets.com/stock/SNDY/news/Solos-Endoscopy-and-TUV-SUD-America-Schedule-Stage-1-ISO-13485-Audit-for-February-26--2013?id=57836&b=y

Solos Endoscopy, Inc. ISO 13485 Certification & CE Mark Project Schedule - MARCH
http://www.solosendoscopy.com/press-releases/SNDY-ISO-13485-CE-Mark-Project-Schedule-March-2013.pdf

= Latest Filings =

www.octmarkets.com/sndy/filings

Year end is December 31st. Quarterly filings are due 45 days after the end of each quarter:

Q1 Jan-Mar 10-Q due May 15th
Q2 Apr-Jun 10-Q due Aug 15th
Q3 Jul-Sep 10-Q due Nov 15th
Q4 Oct-Dec 10-K due Mar 30th (90 days allowed for Q4 which is included in the Annual Report)


= President's Letter/ Information=

August 13, 2013 


Dear Solos Endoscopy, Inc. Shareholders, 

I am very pleased to be able to communicate with our loyal shareholders directly and to give you an 
update on our impressive progress for the second quarter; the three month period ended June 30, 2013. 
Solos Endoscopy, Inc. has been at the forefront of breakthrough medical devices and technologies for the 
treatment and management of diseases for over 25 years. The Company markets over 200 items to the 
endoscopic market and is continuing the development of products that will enhance the ability of medical 
professionals to perform minimally invasive surgical techniques. 
Solos Endoscopy completed the Stage 1 Audit with TÜV SÜD America on Tuesday, February 26, 2013. Solos 
Endoscopy's Quality Manual and 28 Quality System Procedures were reviewed by TÜV SÜD for compliance 
to the international quality system standard ISO 13485:2003, to the European Union's Medical Device 
Directive (MDD 93/42/EEC) and to the Canadian Medical Device Regulations (SOR/98-282). Since the 
completion of the Stage 1 Audit, the Company has been diligently working, with the support of Expert 
Resources, to continually develop, implement and master the Quality Manual and Quality System 
procedures. 

Solos Endoscopy and TÜV SÜD America has scheduled its Stage 2 ISO 13485 Audit to be completed on 
August 16, 2013. Upon successful completion of the Stage 2 Audit, including a review of the Auditor’s report 
and resolution to any corrective actions, Solos will be certified to ISO 13485:2003, the internationally
recognized standard for quality systems for medical device manufacturers. Certification to ISO 13485:2003 
will in turn facilitate Solos Endoscopy obtaining the CE Mark on its MammoView® devices to sell the 
MammoView® in the European Union. According to a 2009 report published by Frost & Sullivan, the 
European Union represents $94 Billion, or 30%, of the worldwide demand for medical instruments. ISO 
13485:2003 certification is also necessary for the company to sell the MammoView® product line in 
Canada. Recently, as part of the process to obtain the CE Mark, Solos Endoscopy has retained Emergo 
Group to act as the Company's authorized representative in Europe. Emergo Group will provide Solos 
assistance related to communications with authorities and importation of Solos instruments into Europe. 
The company previously was successful in completing the Food and Drug Administration (FDA) Level II 
Baseline Inspection in which it received a NAI (No Action Indicated) for the inspection. It is standard for the 
FDA to perform unannounced inspections periodically for medical device manufacturers, and the 
successful inspection by the FDA validates the Company's quality system and its strict adherence to that 
system. 
Solos has several exciting new advances in product development that will change the way minimally 
invasive procedures are utilized in the medical field in order to treat and prevent disease. These products 
will allow the physician to examine organs and tissues within the body without the need for intrusive surgery. 
The Company is currently marketing its next generation breast endoscopy system, the MammoView® 
system, for early breast cancer detection. 
Solos Endoscopy’s core business is the development and marketing of medical technology, applications, 
medical devices and procedural techniques for the screening, diagnosis, treatment and management of 
disease and medical conditions. 


Solos Endoscopy 2nd Quarter 2013 Analysis 

Balance Sheet
 

Solos Endoscopy’s Total Assets decreased to $2,262,785 for the period ended June 30, 2013 from $2,426,883 
for same period in 2012. This represents a decrease of ($164,098), which is mainly attributable to a cash 
and inventory decrease of more than $167,000 for the period ended June 30, 2013 as compared to the 
same period in 2012. 
Solos Endoscopy reduced its Total Liabilities from $214,827 for the period ended June 30, 2012 to just 
$148,000 for period ended June 30, 2013. As a result, the Company has a Positive Net Book Value when it 
posted its financials for the period ended June 30, 2013. 

Income Statement 

Solos Endoscopy showed an increase in sales from $81,752 for period ended June 30, 2012 to $107,955 for 
period ended June 30, 2013. This represents an increase in revenues of $26,203. The Company’s Gross Profit 
increased from $53,214 for period ended June 30, 2012 to $59,520 for the period ended June 30, 2013. The 
Company’s Cost of Goods increased by more than $18,000 as a result of the Company writing off obsolete 
inventory in the 2nd Quarter. 
Solos Endoscopy’s Total Expenses decreased from $642,963 for period ended June 30, 2012 to $177,978 for 
period ended June 30, 2013. The significant decrease in Total Expenses is due to the $450,000 expense the 
Company incurred for stock issued to the CEO in 2012 to guarantee his contract. Otherwise, the Company 
actually reduced its General and Administrative Expense from $192,963 for period ended June 30, 2012 to 
just $177,978 for period ended June 30, 2013. 

Conclusion 

The Company decreased its Net Loss for period ended June 30, 2013 by $471,290. The significant financial 
improvement from the same period in 2012 is due to the fact that the Company will not be charged again 
for the issuance of stock to its CEO to guarantee his contract. This improvement of $450,000, combined with 
an increase in sales of $26,203, resulted in a significant turnaround for the Company. According to 
Management, total salaries are only $45,404 or approximately 40% of sales. The Company has spent 
additional monies on professional fees to complete the TUV Audit which is scheduled to take place on 
August 16, 2013. Therefore, Operating Expenses going forward should remain constant. The reduction of 
these onetime expenses, coupled with an expected increase in sales the 3rd and 4th quarters in 2013, should 
result in a very positive end of the year for Solos Endoscopy.
 
In closing, I want to thank our shareholders for your patience and continued support of Solos Endoscopy. 
We will continue to keep our shareholders updated through regular posting on www.otcmarkets.com and 
Company press releases. To learn more information about the Company and its products visit
 

www.solosendoscopy.com. 

Regards, 
Robert Segersten 
President and CEO 
Solos Endoscopy, Inc 
 Solos Endoscopy, Inc.

http://www.otcmarkets.com/financialReportViewer?symbol=SNDY&id=109547
 

= TUV SUD America:  CE Mark Certification=



= Charts =

One Year Daily:


 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
SNDY
Current Price
Volume:
Bid Ask Day's Range
Wiki
SNDY News: Health Canada's Medical Device Bureau Completes Evaluation of Solos Endoscopic Instruments for Canada 04/30/2014 09:15:00 AM
SNDY News: Solos Endoscopy Reports Financial Results for Period Ended December 31, 2013 04/01/2014 10:05:00 AM
SNDY News: Solos Endoscopy to Begin Distribution of Its Endoscopic Instruments in Canada 02/20/2014 11:39:47 AM
SNDY News: Solos Endoscopy Receives ISO 13485:2003 Certification From TUV SUD America 01/28/2014 01:54:00 PM
PostSubject
#71767  Sticky Note Letter to shareholders: Warhead 07/18/14 07:52:24 PM
#70112  Sticky Note SNDY: BOSTON, MA--(Marketwired - Apr 30, 2014) - ospreyeye 04/30/14 12:20:41 PM
#67301  Sticky Note HERE ARE THE FACTS WHAT WE CAN EXPECT Pennylanepam 01/25/14 06:40:18 PM
#67002  Sticky Note European Union CE Mark Approval Aqua 01/24/14 12:20:35 PM
#62030  Sticky Note Folks, IH Admin [Linda] 08/22/13 03:42:17 PM
#71806   .0004 is worth a gamble IMO. Hulk Hogan is God 07/22/14 01:18:05 PM
#71805   Sorry, but your version is not what slazenger7 07/21/14 06:26:45 PM
#71804   The real question is 'what is this Maciodx 07/21/14 04:56:58 PM
#71803   Delays and dilution aren't going to matter when Jinks 07/21/14 01:40:18 PM
#71802   "The Company has delayed the filing of its Hulk Hogan is God 07/21/14 01:33:01 PM
#71801   If a PR is to follow- I hope lowandaway 07/21/14 12:36:01 PM
#71800   This information was an Officer/Director Disclosure - President's slazenger7 07/21/14 12:30:25 PM
#71799   When we get some news this thing will flyyyyyyyyyy!....guaranteed Jinks 07/21/14 11:49:17 AM
#71798   IMO another total piece of hogwash. Expect Hulk Hogan is God 07/21/14 11:26:26 AM
#71797   I wasn't impressed with the delay either. 8hobbes9 07/21/14 10:55:35 AM
#71796   We've waited nearly 3 months for news & lowandaway 07/21/14 10:45:27 AM
#71795   Do you want to take out the .0008s now? lowandaway 07/21/14 09:55:56 AM
#71794   Is that it? Where is my support from csuck555 07/21/14 09:55:04 AM
#71793   i'll take out the 7s now! csuck555 07/21/14 09:34:58 AM
#71792   Solos Endoscopy experienced significant back orders during the BeauBeau 07/21/14 09:28:51 AM
#71791   We expect sales and cash flow to improve slazenger7 07/21/14 09:22:21 AM
#71790   VNDM is a MM that sells for institutional Pennylanepam 07/21/14 08:57:42 AM
#71789   Let's not forget folks, this was a presidents Aguren 07/20/14 10:18:31 PM
#71788   Thanks blue, I also wanted to add that sharkey1 07/20/14 08:42:59 PM
#71787   Glad to still be on board blueskies. This frecklestocks 07/20/14 06:30:36 PM
#71786   We are pleased to inform the shareholders that blueskies 07/20/14 06:10:45 PM
#71785   Dude, I'm doubtful if anyone here even noticed, Warhead 07/20/14 12:31:12 PM
#71784   Must be dumping time again IMO, we'll stay Hulk Hogan is God 07/20/14 11:15:30 AM
#71783   Are you kidding? Nobody is dumb enough to csuck555 07/20/14 10:06:46 AM
#71782   Everyone buy a million shares at 0.0007 or headnorthw 07/20/14 07:20:33 AM
#71781   This is great news. Back orders means increased frecklestocks 07/20/14 12:43:29 AM
#71780   NOBODY sell in the trips! PPS has absolutely nowhere csuck555 07/19/14 09:46:09 PM
#71779   Witch also can tell us that the sales sharkey1 07/19/14 08:37:39 PM
#71778   PR to follow regarding Canadian Certification and European slazenger7 07/19/14 07:14:42 PM
#71777   yes,lets get off the mat and get in muff1 07/19/14 01:14:28 PM
#71776   Yes indeed! Have to give credit where credit is csuck555 07/19/14 12:41:33 PM
#71775   REVENUES at Last! Canada is next, then Europe. slazenger7 07/19/14 11:47:59 AM
#71774   Solos Endoscopy experienced significant back orders during the slazenger7 07/19/14 11:45:06 AM
#71773   Awesome. Good thing i pocketed another 4 milly csuck555 07/18/14 11:56:27 PM
#71772   It's about time, at least we know what sharkey1 07/18/14 09:28:05 PM
#71771   Lets not forget Aguren 07/18/14 08:46:07 PM
#71770   Yeah! Go SNDY! Marilynt 07/18/14 08:43:18 PM
#71769   Thanks. Bout damn time, huh. Warhead 07/18/14 08:00:02 PM
#71768   Nice post Warhead. soidog 07/18/14 07:56:11 PM
#71767   Letter to shareholders: Warhead 07/18/14 07:52:24 PM
#71763   I agree, it is a skanky way to lowandaway 07/18/14 12:51:29 PM
#71762   Nice way to get hope alive!!! Maciodx 07/18/14 07:33:26 AM
#71761   As long as Segersten can continue to issue BeauBeau 07/18/14 07:26:13 AM
#71759   Next week i may need to start buying csuck555 07/17/14 04:16:11 PM
#71757   $500 in my pocket!! csuck555 07/17/14 04:07:09 PM
#71756   Once in a year SNDY will up -- M-invest 07/17/14 03:24:59 PM
#71755   SNDY don't buy -- bad market -- company M-invest 07/17/14 02:58:21 PM
#71754   If it says 'wait MORE while dilution happens' Hulk Hogan is God 07/17/14 02:21:15 PM
#71753   3.8 mil buy. Warhead 07/17/14 02:17:43 PM
#71752   Why would anyone except flip a coin speculators slazenger7 07/17/14 02:10:34 PM
PostSubject